Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006695 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00006695 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 50 participants.
The verdict
NCT00006695, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well monoclonal antibody therapy, chemotherapy, and peripheral stem cell transplant work in treating patients with relapsed or refractory non-Hodgkin's lymphoma.
Interventions
- DRUG etoposide
- DRUG melphalan
- DRUG carmustine
- PROCEDURE peripheral blood stem cell transplantation
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2000-04-01 |
| Est. Completion | 2014-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006695
The ClinicalTrials.gov registry entry for NCT00006695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which etoposide is the first listed.
NCT00006695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006695 about?
NCT00006695 is a clinical study titled "Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with periphera...
What is the current status of trial NCT00006695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2000-04-01. Estimated completion is 2014-12-16.
What interventions are being tested in trial NCT00006695?
The interventions under investigation include: etoposide (DRUG), melphalan (DRUG), carmustine (DRUG), peripheral blood stem cell transplantation (PROCEDURE), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00006695?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.